Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia - PubMed (original) (raw)
Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia
M Marshall et al. Br J Psychiatry. 2000 Mar.
Abstract
Background: A recent review suggested an association between using unpublished scales in clinical trials and finding significant results.
Aims: To determine whether such an association existed in schizophrenia trials.
Method: Three hundred trials were randomly selected from the Cochrane Schizophrenia Group's Register. All comparisons between treatment groups and control groups using rating scales were identified. The publication status of each scale was determined and claims of a significant treatment effect were recorded.
Results: Trials were more likely to report that a treatment was superior to control when an unpublished scale was used to make the comparison (relative risk 1.37 (95% CI 1.12-1.68)). This effect increased when a 'gold-standard' definition of treatment superiority was applied (RR 1.94 (95% CI 1.35-2.79)). In non-pharmacological trials, one-third of 'gold-standard' claims of treatment superiority would not have been made if published scales had been used.
Conclusions: Unpublished scales are a source of bias in schizophrenia trials.
Similar articles
- Electroconvulsive therapy for schizophrenia.
Tharyan P, Adams CE. Tharyan P, et al. Cochrane Database Syst Rev. 2002;(2):CD000076. doi: 10.1002/14651858.CD000076. Cochrane Database Syst Rev. 2002. PMID: 12076380 Updated. Review. - Benzodiazepines for schizophrenia.
Volz A, Khorsand V, Gillies D, Leucht S. Volz A, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006391. doi: 10.1002/14651858.CD006391. Cochrane Database Syst Rev. 2007. PMID: 17253592 Updated. Review. - Clotiapine for acute psychotic illnesses.
Carpenter S, Berk M. Carpenter S, et al. Cochrane Database Syst Rev. 2001;(1):CD002304. doi: 10.1002/14651858.CD002304. Cochrane Database Syst Rev. 2001. PMID: 11279762 Updated. Review. - Exercise therapy for chronic fatigue syndrome.
Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Larun L, et al. Cochrane Database Syst Rev. 2016 Dec 20;12(12):CD003200. doi: 10.1002/14651858.CD003200.pub6. Cochrane Database Syst Rev. 2016. PMID: 27995604 Free PMC article. Updated. Review. - Exercise therapy for chronic fatigue syndrome.
Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Larun L, et al. Cochrane Database Syst Rev. 2015 Feb 10;(2):CD003200. doi: 10.1002/14651858.CD003200.pub3. Cochrane Database Syst Rev. 2015. PMID: 25674924 Updated. Review.
Cited by
- Family-based interventions versus standard care for people with schizophrenia.
Chien WT, Ma DCF, Bressington D, Mou H. Chien WT, et al. Cochrane Database Syst Rev. 2024 Oct 4;10(10):CD013541. doi: 10.1002/14651858.CD013541.pub2. Cochrane Database Syst Rev. 2024. PMID: 39364773 Review. - Psychological interventions for early-phase schizophrenia: protocol for a systematic review and network meta-analysis.
Feber L, Salanti G, Harrer M, Salahuddin NH, Hansen WP, Priller J, Bighelli I, Leucht S. Feber L, et al. F1000Res. 2024 Sep 16;13:649. doi: 10.12688/f1000research.152191.1. eCollection 2024. F1000Res. 2024. PMID: 39238833 Free PMC article. - Transitional discharge interventions for people with schizophrenia.
Roson Rodriguez P, Chen X, Arancibia M, Garegnani L, Escobar Liquitay CM, Mohammad HA, Franco JV. Roson Rodriguez P, et al. Cochrane Database Syst Rev. 2024 Aug 30;8(8):CD009788. doi: 10.1002/14651858.CD009788.pub3. Cochrane Database Syst Rev. 2024. PMID: 39212182 Review. - Targeted psychological and psychosocial interventions for auditory hallucinations in persons with psychotic disorders: Protocol for a systematic review and meta-analysis.
Fässler L, Bighelli I, Leucht S, Sabé M, Bajbouj M, Knaevelsrud C, Böge K. Fässler L, et al. PLoS One. 2024 Jul 3;19(7):e0306324. doi: 10.1371/journal.pone.0306324. eCollection 2024. PLoS One. 2024. PMID: 38959279 Free PMC article. - Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.
Ibragimov K, Keane GP, Carreño Glaría C, Cheng J, Llosa AE. Ibragimov K, et al. Cochrane Database Syst Rev. 2024 Jul 3;7(7):CD013425. doi: 10.1002/14651858.CD013425.pub2. Cochrane Database Syst Rev. 2024. PMID: 38958149 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical